Bristol-Myers Squibb/$BMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Ticker
$BMY
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
34,100
ISIN
US1101221083
Website
BMY Metrics
BasicAdvanced
$96B
17.61
$2.67
0.41
$2.44
5.27%
Price and volume
Market cap
$96B
Beta
0.41
52-week high
$63.33
52-week low
$39.35
Average daily volume
15M
Dividend rate
$2.44
Financial strength
Current ratio
1.279
Quick ratio
1.095
Long term debt to equity
272.495
Total debt to equity
293.85
Dividend payout ratio (TTM)
90.59%
Interest coverage (TTM)
5.48%
Profitability
EBITDA (TTM)
19,174
Gross margin (TTM)
74.69%
Net profit margin (TTM)
11.38%
Operating margin (TTM)
23.31%
Effective tax rate (TTM)
10.99%
Revenue per employee (TTM)
$1,400,000
Management effectiveness
Return on assets (TTM)
7.25%
Return on equity (TTM)
31.99%
Valuation
Price to earnings (TTM)
17.611
Price to revenue (TTM)
2.003
Price to book
5.5
Price to tangible book (TTM)
-3.57
Price to free cash flow (TTM)
7.292
Free cash flow yield (TTM)
13.71%
Free cash flow per share (TTM)
644.95%
Dividend yield (TTM)
5.19%
Forward dividend yield
5.27%
Growth
Revenue change (TTM)
4.62%
Earnings per share change (TTM)
-188.94%
3-year revenue growth (CAGR)
0.48%
10-year revenue growth (CAGR)
11.45%
3-year earnings per share growth (CAGR)
-1.83%
10-year earnings per share growth (CAGR)
7.04%
3-year dividend per share growth (CAGR)
5.81%
10-year dividend per share growth (CAGR)
5.27%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
Bulls say / Bears say
Bristol Myers Squibb's recent partnership with BioNTech to co-develop the experimental cancer drug BNT327, involving a $1.5 billion upfront payment and potential for over $11 billion in total value, positions the company at the forefront of innovative oncology treatments. (reuters.com)
The U.S. approval and launch of Cobenfy, a novel treatment for schizophrenia, marks a significant expansion into the central nervous system therapeutic area, potentially opening new revenue streams. (biospace.com)
Bristol Myers Squibb's acquisition of Mirati Therapeutics for $4.8 billion, completed in January 2024, enhances its oncology pipeline with promising targeted therapies, potentially driving future growth. (wikipedia.org)
The company's forecasted 2025 revenue of $45.5 billion falls below Wall Street estimates, primarily due to increased generic competition for older drugs, leading to a nearly 4% drop in shares. (reuters.com)
Bristol Myers Squibb reported a net loss of $8.95 billion in 2024, a significant decline from a net income of $8.03 billion in 2023, largely due to substantial expenses related to recent acquisitions. (monexa.ai)
The loss of exclusivity for key cancer drugs like Revlimid, Pomalyst, Sprycel, and Abraxane is expected to result in a revenue decline of approximately 18-20% of the Legacy Portfolio in 2025. (1stoncology.com)
Data summarised monthly by Lightyear AI. Last updated on 24 Jun 2025.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
BMY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul3
Bristol-Myers Squibb
Dividend·Ex-dividend
Aug1
Bristol-Myers Squibb
Dividend·Payment
$0.62Per share
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $96B as of June 25, 2025.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 17.61 as of June 25, 2025.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of June 25, 2025, the dividend rate is $2.44 and the yield is 5.27%. Bristol-Myers Squibb has a payout ratio of 90.59% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment is scheduled for August 01, 2025.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.